Yuziuk J A, Bertoni C, Beccari T, Orlacchio A, Wu Y Y, Li S C, Li Y T
Department of Biochemistry, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA.
J Biol Chem. 1998 Jan 2;273(1):66-72. doi: 10.1074/jbc.273.1.66.
Tay-Sachs disease, an inborn lysosomal disease featuring a buildup of GM2 in the brain, is caused by a deficiency of beta-hexosaminidase A (Hex A) or GM2 activator. Of the two human lysosomal Hex isozymes, only Hex A, not Hex B, cleaves GM2 in the presence of GM2 activator. In contrast, mouse Hex B has been reported to be more active than Hex A in cleaving GM2 (Burg, J., Banerjee, A., Conzelmann, E., and Sandhoff, K. (1983) Hoppe Seyler's Z. Physiol. Chem. 364, 821-829). In two independent studies, mice with the targeted disruption of the Hexa gene did not display the severe buildup of brain GM2 or the concomitant abnormal behavioral manifestations seen in human Tay-Sachs patients. The results of these two studies were suggested to be attributed to the reported GM2 degrading activity of mouse Hex B. To clarify the specificity of mouse Hex A and Hex B and to better understand the observed results of the mouse model of Tay-Sachs disease, we have purified mouse liver Hex A and Hex B and also prepared the recombinant mouse GM2 activator. Contrary to the findings of Burg et al., we found that the specificities of mouse Hex A and Hex B toward the catabolism of GM2 were not different from the corresponding human Hex isozymes. Mouse Hex A, but not Hex B, hydrolyzes GM2 in the presence of GM2 activator, whereas GM2 is refractory to mouse Hex B with or without GM2 activator. Importantly, we found that, in contrast to human GM2 activator, mouse GM2 activator could effectively stimulate the hydrolysis of GA2 by mouse Hex A and to a much lesser extent also by Hex B. These results provide clear evidence on the existence of an alternative pathway for GM2 catabolism in mice by converting GM2 to GA2 and subsequently to lactosylceramide. They also provide the explanation for the lack of excessive GM2 accumulation in the Hexa gene-disrupted mice.
泰-萨克斯病是一种先天性溶酶体疾病,其特征是大脑中GM2蓄积,由β-己糖胺酶A(Hex A)或GM2激活剂缺乏引起。在两种人类溶酶体Hex同工酶中,只有Hex A,而非Hex B,在GM2激活剂存在的情况下能裂解GM2。相比之下,据报道小鼠Hex B在裂解GM2方面比Hex A更具活性(伯格,J.,班纳吉,A.,康策尔曼,E.,和桑德霍夫,K.(1983年)《霍普·赛勒尔生理化学杂志》364卷,821 - 829页)。在两项独立研究中,Hexa基因靶向破坏的小鼠并未表现出人类泰-萨克斯病患者大脑中严重的GM2蓄积或相应的异常行为表现。这两项研究的结果被认为归因于所报道的小鼠Hex B的GM2降解活性。为了阐明小鼠Hex A和Hex B的特异性,并更好地理解泰-萨克斯病小鼠模型的观察结果,我们纯化了小鼠肝脏Hex A和Hex B,并制备了重组小鼠GM2激活剂。与伯格等人的研究结果相反,我们发现小鼠Hex A和Hex B对GM2分解代谢的特异性与相应的人类Hex同工酶并无差异。小鼠Hex A,而非Hex B,在GM2激活剂存在的情况下能水解GM2,而无论有无GM2激活剂,GM2对小鼠Hex B均无反应。重要的是,我们发现,与人类GM2激活剂不同,小鼠GM2激活剂能有效刺激小鼠Hex A对GA2的水解,对Hex B的刺激程度则小得多。这些结果为小鼠中通过将GM2转化为GA2并随后转化为乳糖基神经酰胺的GM2分解代谢替代途径的存在提供了明确证据。它们也解释了Hexa基因破坏的小鼠中缺乏GM2过度蓄积的现象。